scholarly journals Clinical impact of implantable cardioverter-defibrillator in primary prevention of total mortality in non-ischaemic cardiomyopathy: results from a meta-analysis of prospective randomized clinical trials

EP Europace ◽  
2017 ◽  
Vol 20 (FI2) ◽  
pp. f211-f216 ◽  
Author(s):  
Jorge Romero ◽  
Juan Carlos Díaz ◽  
Michael Grushko ◽  
Renato Quispe ◽  
David Briceno ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Primary Prevention ◽  
Implantable Cardioverter Defibrillator ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Total Mortality ◽  
Clinical Impact ◽  
Cardioverter Defibrillator ◽  
Ischaemic Cardiomyopathy

scholarly journals Primary prevention implantable cardioverter defibrillator in patients with non-ischaemic cardiomyopathy: a meta-analysis of randomised controlled trials

BMJ Open ◽  
2017 ◽  
Vol 7 (6) ◽  
pp. e016352 ◽  
Author(s):  
Amr F Barakat ◽  
Marwan Saad ◽  
Akram Y Elgendy ◽  
Amgad Mentias ◽  
Ahmed Abuzaid ◽  
...  
Keyword(s):  
Primary Prevention ◽  
Implantable Cardioverter Defibrillator ◽  
Randomised Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Cardioverter Defibrillator ◽  
Ischaemic Cardiomyopathy ◽  
Randomised Controlled

ASPIRIN FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR EVENTS: AN UPDATED META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS

2019 ◽  
Vol 73 (9) ◽  
pp. 1782
Author(s):  
Rahman Shah ◽  
Aranyak Rawal ◽  
Khalid Najib ◽  
Babar Khan ◽  
Kirstin Hesterberg ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Primary Prevention ◽  
Cardiovascular Events ◽  
Randomized Clinical Trials ◽  
Meta Analysis

scholarly journals Low dose hydroxychloroquine is associated with lower mortality in COVID-19: a meta-analysis of 26 studies and 44,521 patients

2020 ◽  
Author(s):  
Augusto Di Castelnuovo ◽  
Simona Costanzo ◽  
Antonio Cassone ◽  
Roberto Cauda ◽  
Giovanni de Gaetano ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Risk Ratio ◽  
Mortality Risk ◽  
Observational Studies ◽  
Low Dose ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Total Mortality ◽  
Lower Mortality ◽  
Lower Mortality Risk

ABSTRACTBackgroundHydroxychloroquine (HCQ) was proposed as potential treatment for COVID-19, but its association with mortality is not well characterized. We conducted two meta-analyses to evaluate the association between HCQ (with or without azithromycin (AZM)) and total mortality in COVID-19 patients.MethodsArticles were retrieved until October 20th, 2020 by searching in seven databases. Data were combined using the general variance-based method on relative risk estimates.ResultsA total of 26 articles were found (N=44,521 COVID-19 patients, including N=7,324 from 4 randomized clinical trials (RCTs)); 10 studies were valuable for analysing the association of HCQ+AZM. Overall, the use of HCQ was associated with 21% lower mortality risk (pooled risk ratio: 0.79, 95%CI: 0.67 to 0.93; high level of heterogeneity: I2=82%, random effects). This association vanished (1.10, 95%CI: 0.99 to 1.23 and 1.10, 95%CI: 0.99 to 1.23) when daily dose >400 mg or total dose >4,400 mg were used, respectively). HCQ+AZM was also associated with 25% lower mortality risk, but uncertainty was large (95%CI: 0.50 to 1.13; P=0.17). No association was apparent when only pooling the 4 RCTs (13.8% of the overall weight; pooled risk ratio: 1.11, 95%CI: 0.99 to 1.24).ConclusionsHCQ use was not associated with either increased or decreased mortality in COVID-19 patients when 4 RCTs only were evaluated, while a 7% to 33% reduced mortality was observed when observational studies were also included. The association was mainly apparent when pooling studies using lower doses of HCQ. These findings can help disentangling the debate on HCQ use in COVID-19.Key-pointsLow dose hydroxychloroquine was associated with reduced mortality in COVID-19 patients, as seen in observational studies but not in randomised clinical trials, which used high doses of hydroxychloroquine. These findings can help disentangling the debate on hydroxychloroquine use in COVID-19.

scholarly journals Survival of Patients Receiving a Primary Prevention Implantable Cardioverter-Defibrillator in Clinical Practice vs Clinical Trials

JAMA ◽  
2013 ◽  
Vol 309 (1) ◽  
pp. 55 ◽  
Author(s):  
Sana M. Al-Khatib ◽  
Anne Hellkamp ◽  
Gust H. Bardy ◽  
Stephen Hammill ◽  
W. Jackson Hall ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Primary Prevention ◽  
Implantable Cardioverter Defibrillator ◽  
Cardioverter Defibrillator
Sign in / Sign up

Export Citation Format

Share Document